New fluoroquinolone has dual activity against resistant bugs


Physicians will soon have a fourth-generation fluoroquinolone with dual activity against bacteria to treat persons with community-acquired respiratory infections. The FDA recently approved gemifloxacin (Factive, GeneSoft Pharmaceuticals) for the treatment of acute bacterial exacerbation of chronic bronchitis (AECB) caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis and community-acquired pneumonia (CAP) of mild-to-moderate severity caused by S. pneumoniae (including penicillin-resistant strains), H. influenzae, M. catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae. Gemifloxacin will be available in pharmacies by the end of the year.

Related Content
© 2024 MJH Life Sciences

All rights reserved.